1 Min Read
April 18 (Reuters) - Aspen Pharmacare Holdings Limited :
* Aspen’S response to the press reports of 14 and 15 April 2017
* Demonstrated commitment to providing medicines affordably over many years, supply of oncology products in question is no exception
* Aspen will not comment on these public allegations
* Aspen looks forward to opportunity to demonstrate integrity and legality of its practices in context of these legal processes.
* Oncology portfolio in question generated revenue in EU in Aspen's FY ended 30 June 2016 of EUR 60 million (963 mln rand) Source text for Eikon: Further company coverage: (Bengaluru Newsroom)